SPF 100+ sunscreen is more protective against sunburn than SPF 50+ in actual use: Results of a randomized, double-blind, split-face, natural sunlight exposure clinical trial - 19/04/18
Abstract |
Background |
The value of additional photoprotection provided by use of high–sun protection factor (SPF) sunscreens is controversial, and limited clinical evidence exists.
Objective |
To compare the sunburn protection provided by SPF 100+ and SPF 50+ sunscreen in conditions of actual use.
Methods |
A total of 199 healthy men and women (≥18 years) participated in a natural sunlight, single-exposure, split-face, randomized, double-blind study in Vail, Colorado. Each participant wore both sunscreens simultaneously during activities, with no use restrictions other than designation of the treatment area. Erythema was clinically assessed on the day following exposure. Comparative efficacy was evaluated through bilateral comparison of sunburn between treatment areas and erythema score, as evaluated separately for each treatment area.
Results |
Following an average 6.1 ± 1.3 hours of sun exposure, investigator-blinded evaluation identified 55.3% of the participants (110 of 199) as more sunburned on the SPF 50+ protected side and 5% (10 of 199) on the SPF 100+ protected side. After exposure, 40.7% of the participants (81 of 199) exhibited increased erythema scores (by ≥1) on the SPF 50+ protected side as compared with 13.6% (27 of 199) on the SPF 100+ protected side.
Limitations |
Single-day exposure may not extrapolate to benefits of longer-term protection.
Conclusion |
SPF 100+ sunscreen was significantly more effective in protecting against sunburn than SPF 50+ sunscreen in actual use conditions.
Le texte complet de cet article est disponible en PDF.Key words : actual use, high SPF, natural sunlight, photoprotection, sun protection factor, sunburn, sunscreen, outdoor recreation
Plan
| Funding sources: Supported by Johnson & Johnson Consumer Inc. |
|
| Drs Williams, Atillasoy, Maitra, and Wu are employees of Johnson & Johnson Consumer Inc. As sponsor employees and authors, they were involved in the design, management, data analysis, data interpretation, preparation, review, and approval of the article, as well as in the decision to submit it for publication. Dr Farberg serves as a consultant for Johnson & Johnson Consumer Inc. Dr Rigel serves as a consultant for Johnson & Johnson Consumer Inc, Beiersdorf, and Proctor & Gamble. |
|
| Presented in part at the 75th Annual Meeting of the American Academy of Dermatology, Orlando, FL; March 3-7, 2017. |
Vol 78 - N° 5
P. 902 - mai 2018 Retour au numéro
Article précédent
- Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial
- Verena Wally, Alain Hovnanian, Juliette Ly, Hana Buckova, Victoria Brunner, Thomas Lettner, Michael Ablinger, Thomas K. Felder, Peter Hofbauer, Martin Wolkersdorfer, Florian B. Lagler, Wolfgang Hitzl, Martin Laimer, Sophie Kitzmüller, Anja Diem, Johann W. Bauer
- Commentary: Sunscreen sun protection factor (SPF) : Is higher better?
- Kenneth G. Linden
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?